197 related articles for article (PubMed ID: 8201379)
1. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.
Velasquez WS; McLaughlin P; Tucker S; Hagemeister FB; Swan F; Rodriguez MA; Romaguera J; Rubenstein E; Cabanillas F
J Clin Oncol; 1994 Jun; 12(6):1169-76. PubMed ID: 8201379
[TBL] [Abstract][Full Text] [Related]
2. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Rodriguez MA; Cabanillas FC; Velasquez W; Hagemeister FB; McLaughlin P; Swan F; Romaguera JE
J Clin Oncol; 1995 Jul; 13(7):1734-41. PubMed ID: 7602363
[TBL] [Abstract][Full Text] [Related]
3. ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience.
Wang WS; Chiou TJ; Liu JH; Fan FS; Yen CC; Tung SL; Chen PM
Jpn J Clin Oncol; 1999 Jan; 29(1):33-7. PubMed ID: 10073149
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
Romaguera JE; Rodriguez MA; Hagemeister FB; McLaughlin P; Swan F; Moore DF; Sarris AH; Younes A; Hill D; Cabanillas F
Invest New Drugs; 1994; 12(3):217-22. PubMed ID: 7896540
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
6. ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
Choi CW; Paek CW; Seo JH; Kim BS; Shin SW; Kim YH; Kim JS
J Korean Med Sci; 2002 Oct; 17(5):621-4. PubMed ID: 12378012
[TBL] [Abstract][Full Text] [Related]
7. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
8. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).
Velasquez WS; Cabanillas F; Salvador P; McLaughlin P; Fridrik M; Tucker S; Jagannath S; Hagemeister FB; Redman JR; Swan F
Blood; 1988 Jan; 71(1):117-22. PubMed ID: 3334893
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Harting R; Venugopal P; Gregory SA; O'brien T; Bogdanova E
Clin Lymphoma Myeloma; 2007 May; 7(6):406-12. PubMed ID: 17621406
[TBL] [Abstract][Full Text] [Related]
10. Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin.
Oztürk MA; Barişta I; Altundağ MK; Türker A; Yalçin S; Celik I; Güllü I; Güler N; Ozişik Y; Kars A; Kansu E; Baltali E; Tekuzman G
Chemotherapy; 2002 Dec; 48(5):252-8. PubMed ID: 12476042
[TBL] [Abstract][Full Text] [Related]
11. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
Bi J; Espina BM; Tulpule A; Boswell W; Levine AM
J Acquir Immune Defic Syndr; 2001 Dec; 28(5):416-21. PubMed ID: 11744828
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
Martín A; Redondo AM; Dlouhy I; Salar A; González-Barca E; Canales M; Montes-Moreno S; Ocio EM; López-Guillermo A; Caballero D;
Br J Haematol; 2016 Apr; 173(2):245-52. PubMed ID: 26847165
[TBL] [Abstract][Full Text] [Related]
13. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.
Labrador J; Cabrero-Calvo M; Pérez-López E; Mateos MV; Vázquez L; Caballero MD; García-Sanz R
Ann Hematol; 2014 Oct; 93(10):1745-53. PubMed ID: 24863692
[TBL] [Abstract][Full Text] [Related]
14. Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Romaguera JE; Hagemeister FB; McLaughlin P; Rodriguez MA; Bachier C; Preti H; Sarris AH; Weber D; Younes A; Cabanillas F
Leuk Lymphoma; 1998 Dec; 32(1-2):97-106. PubMed ID: 10037005
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
van Besien K; Rodriguez A; Tomany S; Younes A; Donato M; Sarris A; Giralt S; Mehra R; Andersson B; Gajewski J; Champlin R; Cabanillas F
Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669
[TBL] [Abstract][Full Text] [Related]
16. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
Cabanillas F; Velasquez WS; McLaughlin P; Jagannath S; Hagemeister FB; Redman JR; Swan F; Rodriguez MA
Semin Hematol; 1988 Apr; 25(2 Suppl 2):47-50. PubMed ID: 3041599
[TBL] [Abstract][Full Text] [Related]
17. A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma.
Sym SJ; Lee DH; Kang HJ; Nam SH; Kim HY; Kim SJ; Eom HS; Kim WS; Suh C
Cancer Chemother Pharmacol; 2009 Jun; 64(1):27-33. PubMed ID: 18839172
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
19. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
[TBL] [Abstract][Full Text] [Related]
20. ESHAP versus rituximab-ESHAP in frail patients with refractory diffuse large B-cell lymphoma.
Avilés A; Neri N; Huerta-Guzmán J; de Jesús Nambo M
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):125-8. PubMed ID: 20371445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
